Eli Lilly LLY-N on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly (NYSE:LLY) is scheduled to announce Q4 earnings results on Thursday, February 6th, before market open. The consensus EPS Estimate is $5.11 (+105.2% Y/Y) and the consensus Revenue ...

"We’ve got sun-loving plants like coral bark Japanese maples, swamp banksia, lilly pilly, and grevilleas to provide shelter and privacy to the house," says Graham. Natalie Hunfalvay Graham ...

US pharma giant Eli Lilly is gearing up to launch the anti-diabetes and weight loss drug Mounjaro in India by 2025, pending necessary regulatory approvals, the company’s top official told News18. This ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion ...

Trump removes Joint Chiefs chairman Gen. CQ Brown in purge of military leaders Starting in 2025, no NFL games will be exclusively broadcast on traditional TV Pentagon says it will cut 5,400 ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Eli Lilly (LLY) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

Eli Lilly last week terminated a Phase II trial of its investigational relaxin analog volenrelaxin in chronic kidney disease, according to an update to the study’s clinicaltrials.gov webpage. Lilly is ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...